Loading...
Rhythm Pharmaceuticals Q1 2025 Earnings Report
Rhythm Pharmaceuticals reported its first quarter 2025 financial results, highlighting strong revenue growth from IMCIVREE, progress in clinical trials for setmelanotide and bivamelagon, and a solid cash position.
Key Takeaways
Rhythm Pharmaceuticals reported strong first quarter 2025 results with net product revenue from global sales of IMCIVREE reaching $37.7 million. The company achieved significant progress in its clinical trials, with the pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity meeting its primary endpoint, and regulatory submissions on track for Q3 2025. Additionally, the company's cash on-hand is expected to support operations into 2027.
First quarter 2025 net product revenue from global sales of IMCIVREE was $37.7 million.
The pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity met its primary endpoint with a -19.8% placebo-adjusted BMI reduction.
U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity are on track to be completed in the third quarter of 2025.
Cash on-hand is expected to support planned operations into 2027.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Revenue by Segment
Rhythm Pharmaceuticals Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comOutside United States Revenue
CapyFin.com Forward Guidance
Rhythm Pharmaceuticals anticipates Non-GAAP Operating Expenses for the year ending December 31, 2025, to be approximately $285 million to $315 million, with cash on-hand expected to support planned operations into 2027.
Positive Outlook
- Submit supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency for setmelanotide for the treatment of acquired HO in the third quarter of 2025.
- Announce topline data from the bivamelagon Phase 2 trial in acquired HO in the third quarter of 2025.
- Complete enrollment in the setmelanotide Phase 2 trial in Prader-Willi syndrome (PWS) in the second half of 2025.
- Complete enrollment in the Phase 1, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired hypothalamic obesity in the second half of 2025.
- Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity in the second half of 2025.